Alloimmunization consists of the induction of immunity in response to foreign antigen(s) encountered through exposure to cells or tissues from a genetically different member of the same species. [1] It is one of the major complications of regular blood transfusions, particularly in patients who are chronically transfused. Blood group antigens can be immunogenic in individuals who lack the corresponding antigen on their red blood cells (RBCs). This mismatch can occur during transfusion of antigen positive blood into someone who is antigen-negative, or during pregnancy when the mother lacks a blood group antigen that is contained on the fetal RBCs. In the former case, this can result in immunization of the transfusion recipient and the production of alloantibody that may cause a hemolytic transfusion reaction. [2] Observational studies in random patients, who most often receive incidental transfusions, and pregnant women estimated the antibody prevalence between <1-3%. This incidence increases in multiply transfused patients and transfusion-dependent patients which include patients with sickle cell disease (SCD), severe thalassemia syndromes, severe aplastic anemia, myelodysplastic syndromes, and other congenital or acquired chronic anemias. The incidence in these patient groups has been reported to vary from 8% to 76% among different countries. [3] The reported prevalence of alloimmunization in multi-transfused patients in India is comparatively low varying from approximately 3% to 10%. [4] [5] [6] In the study by Dhawan et al. [7] in this journal, the incidence of red cell alloimmunization is relatively low (5.64%), which is in accordance with studies from India. This low rate of alloimmunization may be explained by the presumed high phenotypic compatibility between blood donors and the patients. The genetic disparity between patient and donor RBC phenotypes is considered to be the main reason for the high immunization risk in patients with SCD in USA. Especially, C, Fya, Fyb, Jkb and S RBC antigens are signifi cantly less frequent (P < 0.001) in the predominantly black sickle cell patients than in the predominantly white donors [8] and antibodies against these antigens are more frequently found than in most other patients. Studies in sickle cell patients performed in Jamaica [9] with a closer racial matching of donor and recipients, showed a 3 times lower immunization risk compared with European and American studies (9% vs. 27%). This led to the policy to prophylactically match donor RBCs for RH and K antigens in patients with hemoglobinopathies.
Other factors implicated in RBC alloantibody formation include recipient sex and age, history of pregnancy, number and timing of blood transfusions, recipient clinical diagnosis and treatment, genetic factors related to the antigenic response, and racial differences between donors and recipients. [10] The formation of red cell antibodies may be infl uenced by the patients' age at which the transfusions are given or when chronic transfusion therapy is started. Four studies on RBC alloimmunization performed in (preterm) neonates who received multiple transfusions during the first 3-4 months of life did not encounter any RBC antibodies. [11] Furthermore, in hemoglobinopathy patients it has been shown that alloimmunization risk was signifi cantly lower in patients who started transfusion therapy at a very young age (<3 years) compared with those who started later in life. [12] Dhawan et al. [7] in this issue also observed the same. Age at fi rst transfusion was significantly higher in alloimmunized (23.28 months) than nonimmunized patients (14.43 months) (P = 0.042). An immature immune system and some form of acquired immune tolerance to allogeneic RBC antigens are held responsible for the reduced alloimmunization risk.
Other than ABO antibodies most other clinically signifi cant antibodies to red cell surface antigens are immunoglobulin G (IgG) and produced in response to immunization by antigen-positive red cells: Either donor red cells following transfusion or cells of fetal origin, following fetomaternal hemorrhage during pregnancy or at parturition. [3] The antigens most frequently involved in alloimmunization belong to the Rh, Kell, Kidd, Duffy, Lewis and MNS blood group systems. [10] Dhawan et al. [7] in this issue also reported that out of total 23 alloantibodies detected in 319 transfused thalassemic patients, 87.17% belonged to Rh and Kell blood group system. These antibodies may result in clinically signifi cant hemolytic transfusion reactions, difficulty in cross-matching blood, decrease in RBC survival and an increased transfusion requirement. [13] In addition, downstream effects resulting from RBC clearance can lead to multiple organ failure, electrolyte perturbations, coagulopathy, and in some cases, death. Humoral alloimmunization to RBC antigens is thus a signifi cant clinical problem.
It is thus important to detect these alloantibodies in a timely fashion so that antigen-negative blood could be provided to patients. Antibody screening is commonly done by indirect coombs test by utilizing screening cell panels as most clinically signifi cant antibodies are of IgG type. Traditionally, these cell panels are procured from the western countries and thus they represent the antigens commonly present in western populations in addition to being costly and diffi cult to procure. It is thus important to develop cell panels derived from local ethnic groups so that clinically signifi cant antibodies against antigens in local population could be detected such as antibodies to In (b−) in Asians. [3, 6] However, this approach of providing antigen-negative blood after development of alloantibody is time consuming and costly and at times it becomes diffi cult to provide antigen-negative blood to patients who have developed multiple alloantibodies. It is thus important to adopt policies for prevention of alloantibody formation in multi-transfused or transfusion-dependent patients.
In addition to alloantibodies, chronically transfused thalassemics are also prone to develop red cell autoantibodies, which can complicate transfusion therapy further. Dhawan et al. [7] in this issue of journal reported 28.2% of their patients developed autoantibodies. The pathogenesis of erythrocyte autoantibody formation following transfusion is not well-understood. However, clinical evidence of autoimmune haemolytic anaemia (AIHA) has been seen with high amounts of RBC-associated IgG. [14] It was also suggested that alloantibody binding to the RBCs could lead to conformational changes of the antigenic epitope that ultimately stimulates production of autoantibodies. [15] It is possible that certain people are genetic responders who have an increased tendency to develop RBC autoantibodies and the tendency toward autoantibody formation could refl ect an overall dysfunction of the immune system. [16] Red cell autoantibodies can result in clinical hemolysis called AIHA, and in difficulty in cross-matching blood. Patients with autoantibodies may have a higher transfusion rate and often require immunosuppressive drugs or alternative treatments including intravenous IgG and rituximab (anti-CD20 monoclonal antibody). Philip and Jain 2014 [17] in this issue reported a case of thalassemia patient who developed autoantibodies with severe hemolysis and difficulty in finding suitable unit of blood. The case was successfully managed by Rituximab along with extended phenotype matched blood. However, one should be careful in interpretation of positive direct antiglobulin test (DAT) in a multi-transfused patient as delayed hemolytic reactions can also give rise to positive DAT, mixed field reaction and clinical hemolysis. This should be ruled out by elution and serial monitoring of DAT in such patients.
Approaches for prevention or treatment of alloimmunization range from provision of RBCs matched for all the major antigens associated with clinically signifi cant antibodies to blood matched only for antibodies that have already been made. In the fi rst approach an extended RBC phenotype (ABO, Rh, Kell, Kidd, Duffy, Lewis, MNS) of the patient is done before commencing transfusion therapy and antigen-matching for C, E and K antigens is performed for patients without prior alloantibody formation. [10] However, the expense and the feasibility of antigen-matched blood may not permit such a transfusion approach in some medical centers. For economic reasons, such centers can match the blood for antibodies common in their populations. The second approach involves transfusing matched blood only for patients who fi rst proved to be "antibody producers" as this may reduce expenses and increase the availability of matched blood. [8] 
